Barclays’s Foghorn Therapeutics FHTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $334K | Buy |
70,814
+30,924
| +78% | +$146K | ﹤0.01% | 3252 |
|
|
2025
Q1 | $145K | Sell |
39,890
-11,719
| -23% | -$42.6K | ﹤0.01% | 3518 |
|
|
2024
Q4 | $245K | Buy |
51,609
+11,689
| +29% | +$55.5K | ﹤0.01% | 3423 |
|
|
2024
Q3 | $371K | Buy |
39,920
+26,228
| +192% | +$244K | ﹤0.01% | 3156 |
|
|
2024
Q2 | $79K | Sell |
13,692
-5,550
| -29% | -$32K | ﹤0.01% | 3489 |
|
|
2024
Q1 | $129K | Sell |
19,242
-13,662
| -42% | -$91.6K | ﹤0.01% | 3547 |
|
|
2023
Q4 | $212K | Buy |
32,904
+29,341
| +823% | +$189K | ﹤0.01% | 3482 |
|
|
2023
Q3 | $18K | Sell |
3,563
-508
| -12% | -$2.57K | ﹤0.01% | 3925 |
|
|
2023
Q2 | $29K | Sell |
4,071
-6,055
| -60% | -$43.1K | ﹤0.01% | 3881 |
|
|
2023
Q1 | $62K | Buy |
10,126
+4,729
| +88% | +$29K | ﹤0.01% | 3718 |
|
|
2022
Q4 | $34K | Buy |
5,397
+4,545
| +533% | +$28.6K | ﹤0.01% | 3896 |
|
|
2022
Q3 | $7K | Sell |
852
-156
| -15% | -$1.28K | ﹤0.01% | 4290 |
|
|
2022
Q2 | $14K | Sell |
1,008
-2,170
| -68% | -$30.1K | ﹤0.01% | 4208 |
|
|
2022
Q1 | $48K | Buy |
+3,178
| New | +$48K | ﹤0.01% | 4018 |
|